AVEO Pharmaceuticals, Inc.
AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer
Published in Women's Health Law Weekly, March 29th, 2009
AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). This new trial expands on the Company’s broad development program for AV-951, a novel triple VEGF receptor inhibitor being studied in multiple single agent and combination clinical trials across a variety of cancer types including renal cell carcinoma, breast cancer, colorectal cancer and now, lung cancer. The Company launched the Phase 1b portion of this new open-label...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
More Articles from Women's Health Law Weekly
- Engage Her, Inc.
Engage Her Announces First Multicultural Women’s Leadership Conference - FEW
FEW Releases 2008 Employment Statistics with Interactive Map - Food Poisoning
Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning - HIV/AIDS
U.S. Food and Drug Administration Approves New Female Condom - HIV/AIDS
University of Kentucky publishes research in HIV/AIDS - Life Sciences
Research on life sciences published by scientists at Center for Health Policy Research and Development - More from this issue of Women's Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
